Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2005
Published online before print November 3, 2005, doi: 10.1161/01.RES.0000194324.29363.82
A more recent version of this article appeared on December 9, 2005
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
97/12/1253    most recent
01.RES.0000194324.29363.82v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krysiak, O.
Right arrow Articles by Schönfelder, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krysiak, O.
Right arrow Articles by Schönfelder, G.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*High Risk Pregnancy
Related Collections
Right arrow Other hypertension
Right arrow Gene expression
Right arrow Gene regulation
Right arrow Growth factors/cytokines
Right arrow Genetics of cardiovascular disease

Submitted on December 13, 2004
Revised on October 6, 2005
Accepted on October 24, 2005

Soluble Vascular Endothelial Growth Factor Receptor-1 (sFLT-1) Mediates Downregulation of FLT-1 and Prevents Activated Neutrophils From Women With Preeclampsia From Additional Migration by VEGF

Oliver Krysiak ; Anja Bretschneider ; Enhong Zhong ; Jessie Webb ; Hartmut Hopp ; Stefan Verlohren ; Norbert Fuhr ; Malgorzata Lanowska ; Andreas Nonnenmacher ; Roland Vetter ; Joachim Jankowski ; Martin Paul ; and Gilbert Schönfelder *

From the Institute of Clinical Pharmacology and Toxicology (O.K., A.B., E.Z., J.W., R.V., M.P., G.S.) and the Department of Gynecology and Obstetrics (H.H., S.V., N.F.), Medizinische Klinik für Endokrinologie und Nephrologie (J.J.), Charité-Universitaetsmedizin Berlin, Germany.

* To whom correspondence should be addressed. E-mail: gilbert.schoenfelder{at}charite.de.

Neutrophil activation and increased migration is associated with preeclampsia and is resolved after delivery. Preeclampsia is an inflammatory disorder where altered levels of vascular endothelial growth factor (VEGF) and the circulating soluble fms-like tyrosine kinase 1 (sFlt-1) have a pathogenic role. VEGF, by binding to FLT-1, induces leukocytic chemotaxis. We studied expression and function of FLT-1 in maternal neutrophils during preeclampsia and normal pregnancies. Analysis of maternal neutrophils showed the relationship between FLT-1 expression and week of gestation. Preeclamptic women express lower FLT-1 and sFLT-1 in neutrophils. In contrast, serum levels of sFLT-1 in patients with preeclampsia are increased and, therefore, inhibit upregulation of FLT-1 in neutrophils by neutralizing VEGF. VEGF-dependent FLT-1 expression is regulated by changing FLT-1-promoter activity. Promoter activity is decreased by sFLT-1. In vitro experiments demonstrated that migration of neutrophils is regulated by VEGF via FLT-1 and excess of sFLT-1. Thus, VEGF-dependent migration of neutrophils is decreased during preeclampsia as a consequence of excess circulating sFlt1. But, they still increase migration by fMLP and, therefore, migration of neutrophils from preeclamptic women is highly activated when compared with the normotensive group. In conclusion, besides being involved in inducing an antiangiogenic state in the serum, excess of sFLT-1 seems to prevent activated neutrophils from women with preeclampsia from additional migration by VEGF. We provide evidence that neutrophils may be involved in the pathophysiology of pregnancy-related hypertensive disorders.


Key words: migration • neutrophils • preeclampsia • pregnancy • VEGF receptor 1




This article has been cited by other articles:


Home page
Circ. Res.Home page
V. Muthig, R. Gilsbach, M. Haubold, M. Philipp, T. Ivacevic, M. Gessler, and L. Hein
Upregulation of Soluble Vascular Endothelial Growth Factor Receptor 1 Contributes to Angiogenesis Defects in the Placenta of {alpha}2B-Adrenoceptor Deficient Mice
Circ. Res., September 28, 2007; 101(7): 682 - 691.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
D. Menendez, A. Inga, J. Snipe, O. Krysiak, G. Schonfelder, and M. A. Resnick
A Single-Nucleotide Polymorphism in a Half-Binding Site Creates p53 and Estrogen Receptor Control of Vascular Endothelial Growth Factor Receptor 1
Mol. Cell. Biol., April 1, 2007; 27(7): 2590 - 2600.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
G. Girardi, D. Yarilin, J. M. Thurman, V. M. Holers, and J. E. Salmon
Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction
J. Exp. Med., September 4, 2006; 203(9): 2165 - 2175.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. Menendez, O. Krysiak, A. Inga, B. Krysiak, M. A. Resnick, and G. Schonfelder
A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network
PNAS, January 31, 2006; 103(5): 1406 - 1411.
[Abstract] [Full Text] [PDF]